Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Yesterday, Amgen announced that it would launch the U.S.’s first marketed ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

“Simply because Amgen discovered the purified gene does not give them the right to the gene in its natural environment,” says Mark Hofer, an attorney at Brown, Rudnick, Freed & Gesmer (Boston ...

Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone ...